@Article{096504018X15267574931782,
AUTHOR = {Takashi Saito, Atsuo Okamura, Junichiro Inoue, Daisuke Makiura, Hisayo Doi, Kimikazu Yakushijin, Hiroshi Matsuoka, Yoshitada Sakai#, Rei Ono},
TITLE = {Anemia Is a Novel Predictive Factor for the Onset of Severe Chemotherapy-Induced Peripheral Neuropathy in Lymphoma Patients Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone Therapy},
JOURNAL = {Oncology Research},
VOLUME = {27},
YEAR = {2019},
NUMBER = {4},
PAGES = {469--474},
URL = {http://www.techscience.com/or/v27n4/48560},
ISSN = {1555-3906},
ABSTRACT = {Chemotherapy-induced peripheral neuropathy (CIPN) frequently occurs in lymphoma patients receiving
R-CHOP, a drug combination therapy. Although severe CIPN may lead to reduction and/or discontinuation
of the medication, predictive factors of CIPN have not been investigated sufficiently to date. We performed
a retrospective exploratory research to determine associations between prevalence of severe CIPN and sociodemographic data, health characteristics, and medical conditions such as anemia at initial diagnosis. Forty
patients (indolent lymphoma, n=9; diffuse large B-cell lymphoma; n=31) received R-CHOP therapy from
September 2009 to July 2014. The median age of patients was 58 years (range=27–76 years). Statistical analyses were applied to the patients, who were divided into two groups: mild CIPN (no symptoms or grade 1
according to the CTCAE version 3.0 program) and severe CIPN patients (grade 2 or higher). Forward stepwise
logistic regression analyses were performed using the following variables: sex, BMI, BSA, hyperglycemia,
malnutrition, and anemia. Severe CIPN occurred in seven patients (17.5%). Gender and anemia remained
following the stepwise procedure, and anemia predicted severe CIPN significantly (OR=19.45, 95% confidence interval=1.52–171.12). Our study suggests that anemia at initial diagnosis could be a predictive factor
of R-CHOP-induced CIPN.},
DOI = {10.3727/096504018X15267574931782}
}